Trial Profile
A Randomized, Double-Blinded, Safety and Pharmacokinetic Study of Escalating Single Doses of Hepalatide in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Feb 2022
Price :
$35
*
At a glance
- Drugs Hepalatide (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Shanghai HEP Pharmaceutical
- 20 Jan 2017 New trial record